Assessment of cetuximab-induced infusion reactions and administration rechallenge at an academic medical center
Sign Up to like & getrecommendations! Published in 2017 at "Medical Oncology"
DOI: 10.1007/s12032-017-0902-9
Abstract: Cetuximab is approved for treatment of squamous cell carcinoma of the head and neck (SCCHN). Cetuximab is generally well tolerated, but does carry a black box warning for infusion reactions (IRs). Incidence of IR in… read more here.
Keywords: incidence; infusion reactions; assessment cetuximab; cetuximab ... See more keywords